
Nov 17, 2026 · 29 min
Market sell-off puts support levels and Nvidia to the test
Dow Plunges 900 Points On Salesforce Carnage: Paycom, Ascendis, TGTX In Focus
The episode weighs whether battered indexes can form a rally attempt while software weakness spreads and Nvidia offers a potential catalyst.
- 1Major indexes tested or broke key support as negative breadth and weakness across sectors raised pressure on the market.
- 2Paycom, Ascendis Pharma, and TG Therapeutics showed relative strength despite broad selling and remained technically constructive.
- 3Nvidia’s earnings beat and upbeat outlook became the market’s next test for a possible rally attempt.
Don't miss
Nvidia beats on revenue and earnings, raises its outlook, and becomes the immediate test of whether the market can mount a rally attempt.
The brief
Alissa Coram and Ken Shreve assess a broad sell-off that pushed the Nasdaq, S&P 500, Dow, and Russell 2000 toward or below key support levels.
The hosts argue that investors should wait for a rally attempt and follow-through rather than call a bottom, especially with indexes below important moving averages.
Software, financial, healthcare, blue-chip, and small-cap stocks all weakened, while lower Treasury yields and uncertainty around Fed minutes added pressure.
Paycom held above its 50-day moving average, while Ascendis Pharma and TG Therapeutics showed constructive bases or orderly pullbacks despite the market’s weakness.
Nvidia beat on revenue and earnings and raised its outlook, making its conference call, China shipments, and future demand central to the market’s next test.
What was said on this episode
15 statements · 9 positive · 4 negative · 2 neutral
Nasdaq had declined approximately 13.5% from its recent high.
“the NASDAQ did pull back about 13.5% off its high”
Listen at 3:24
Nasdaq breadth was negative, with decliners outnumbering advancers three to one.
“the breadth on the NASDAQ was pretty negative all day. Three to one, you know, decliners beating advancers”
Listen at 4:38
Current market selling will eventually lead to a new round of buying.
“all of the selling is eventually going to pave the way for a new round of buying”
Listen at 8:00
Salesforce declined approximately 9% during the session.
“Salesforce really, really took a beating today. I mean, this was a 9%. At one point, it was a 9% decline for Salesforce.”
Listen at 10:49
The Federal Reserve will most likely raise rates by 25 basis points.
“The Fed is most likely going to be hiking rates by a quarter point.”
Listen at 14:25
The government is taking steps to reduce fraud in health insurance.
“I think the government is taking steps to... curtail fraud in this area.”
Listen at 16:44
Paycom currently appears technically healthy.
“I think it still looks pretty... Pretty healthy here.”
Listen at 18:52
Workforce-management and payroll software firms are performing strongly.
“These workforce management, human resource, payroll type software. Firms that basically manage the back end for companies are really doing well.”
Listen at 19:01
Ascendis is currently profitable.
“It is a profitable biotech.”
Listen at 20:24
Ascendis has a market capitalization of approximately $16–17 billion.
“It's a big company, $16 billion, $17 billion market cap.”
Listen at 20:34
Ascendis has a drug-delivery technology called TransCon.
“This company has a drug delivery technology that's referred to as Transcon.”
Listen at 20:53
TransCon extends the duration of medication activity inside the body.
“it's basically used to extend how long... a medication stays active inside the body.”
Listen at 21:00
TG Therapeutics’ Briamvi is approaching $1 billion in annual revenue.
“it is approaching $1 billion in annual revenue”
Listen at 23:17
TG Therapeutics is a strong, leading, profitable biotech.
“This is a really strong and leading profitable biotech.”
Listen at 24:41
The market could begin a very strong rally attempt tomorrow.
“Who knows? We could see a very, very strong first day of a rally attempt tomorrow.”
Listen at 27:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.